NEW YORK, Dec. 19 – Cambridge Antibody Technology of Melbourn, UK, has licensed access to Incyte’s LifeSeq Gold database and obtained options for the rights to develop products based on the data, the companies said Wednesday.
CAT will use the data as well as cDNA clones Incyte provides to develop antibody therapeutic products. CAT also has the right to gain the exclusive licences from Incyte develop treatments aimed at protein targets in Incyte’s database.
In exchange, CAT will pay a licence fee, plus milestones and royalties to Incyte.
“CAT has already demonstrated the power of combining antibody phage display and genomics-based target discovery, and this agreement adds a significant new source of genomics-derived targets to fuel CAT's drug development pipeline," David Chiswell, CEO of CAT, said in a statement.
CAT has developed technologies for to use human monoclonal antibodies for drug discovery and drug development. The company is currently running clinical trials for six of its therapeutic antibodies.
The company employs approximately 250 people.